Steven M. Paul, MD
Steven Paul, M.D., is a physician-scientist, biopharmaceutical company executive, entrepreneur
and expert in drug discovery and development. Dr. Paul began his career at the National
Institutes of Health (NIH), where he was a laboratory/branch chief and later became the
scientific director of the National Institute of Mental Health. After his time at the NIH, Dr. Paul
spent 17 years at Eli Lilly & Co., most recently as executive vice president for science and
technology (head of research & development) and president of the Lilly Research laboratories
overseeing R&D in all of Lilly’s therapeutic areas and the successful development of a number
of Lilly’s largest products in CNS, diabetes, inflammation, and oncology. Following his tenure at
Lilly, Dr. Paul joined Third Rock Ventures based in Boston and founded several now public
biopharmaceutical companies, including Sage Therapeutics (NASDAQ: SAGE) and Voyager
Therapeutics (NASDAQ: VYGR), and now serves on their boards. He is also the former director
of the Appel Alzheimer Disease Research Institute at Weill Cornell Medical College and is
currently a professor of psychiatry and neurology at Washington University of St. Louis School
of Medicine.
Dr. Paul currently serves as chairman of the board, president, and chief executive officer of
Karuna Therapeutics (NASDAQ: KRTX), a clinical-stage, public biopharmaceutical company
developing treatments for severe neuropsychiatric conditions, such as schizophrenia and
dementia-related psychosis. In addition to his role at Karuna, he also serves as a director of Sage
Therapeutics, Voyager Therapeutics, Alnylam Pharmaceuticals (NASDAQ: ALNY), and is
chairman of the board of the Foundation for the NIH (FNIH).
Dr. Paul has authored or co-authored more than 550 papers and book chapters. He is an elected
Fellow of the American Association for the Advancement of Science and a member of the
National Academy of Medicine. He is also an elected Fellow Emeritus of the American College
of Neuropsychopharmacology (ACNP) and served as ACNP President (1999). Dr. Paul is the
Chairman of the Board of the Foundation for the NIH (FNIH) and previously served on the
Science Board of the U.S. Food and Drug Administration (FDA) in addition to serving on many
other advisory committees and receiving many awards and honors for his scientific research.